Cancer is considered as one of the most serious health problems today. The discovery of
nitrogen mustard as an alkylating agent in 1942, opened a new era in the cancer …

Solid tumours contain regions at very low oxygen concentrations (hypoxia), often
surrounding areas of necrosis. The cells in these hypoxic regions are resistant to both …

The purpose of this article is to provide an overview of the latest applications of
organophosphorus compounds (OPs) that exhibit biological activity. A large family of OPs …

Phosphonic acids are rarely found in drug candidate molecules, despite the potential of this
functional group to provide unique binding interactions with a target enzyme or receptor …

Bioactivatable protecting groups represent an enormously powerful tool to increase
bioavailability or to generally help deliver drugs to cells. This approach is particularly …

A series of achiral hypoxia-activated prodrugs were synthesized on the basis of the DNA
cross-linking toxin of the prodrug, ifosfamide. The hypoxia-selective cytotoxicity of several of …

Anticancer prodrugs designed to target specifically tumor cells should increase therapeutic
effectiveness and decrease systemic side effects in the treatment of cancer. Over the last 20 …

Inhibiting glycolysis remains an aspirational approach for the treatment of cancer. We have
previously identified a subset of cancers harbouring homozygous deletion of the glycolytic …

Chemotherapy is central to oncology, perceived to operate only on prolific cancerous tissue.
Yet, many non-neoplastic tissues are more prolific compared with typical tumors …

Nitroaromatic compounds (ArNO2) maintain their importance in relation to industrial
processes, environmental pollution, and pharmaceutical application. The manifestation of …